×

Dosage forms of risedronate

DC CAFC
  • US 7,645,460 B2
  • Filed: 11/23/2005
  • Issued: 01/12/2010
  • Est. Priority Date: 05/24/2004
  • Status: Active Grant
First Claim
Patent Images

1. An oral dosage form having pharmaceutically effective absorption comprising:

  • (a) from about about 1 mg to about 250 mg of a bisphosphonate selected from the group consisting of risedronate and acids, salts, and esters thereof;

    (b) from about 10 mg to about 500 mg of EDTA; and

    (c) a delayed release mechanism to immediately release the risedronate and the EDTA in the small intestine;

    wherein said composition weighs no greater than 1 gram.

View all claims
  • 7 Assignments
Timeline View
Assignment View
    ×
    ×